LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
Rhea-AI Summary
Lunai Bioworks (Nasdaq:LNAI) will implement a 1-for-8 reverse stock split of its common stock, effective 12:01 a.m. ET on May 22, 2026. Shares will begin trading on a split-adjusted basis that day under LNAI with new CUSIP 29350E302.
The split, approved by stockholders and set by the board, is intended to increase the per-share price to help regain compliance with Nasdaq Listing Rule 5550(a)(2). Outstanding shares will decline from about 36.27 million to about 4.53 million, with no change to par value or authorized shares, and fractional shares rounded up.
AI-generated analysis. Not financial advice.
Positive
- Reverse split aims to support Nasdaq $1.00 minimum bid compliance
- Outstanding shares reduced from ~36.27M to ~4.53M
- No change to authorized share count or par value
- Fractional shares rounded up to the next whole share
Negative
- Company previously executed a 1-for-10 reverse split on Sept. 30, 2025
- Reverse split signals prior share price below Nasdaq minimum bid level
News Market Reaction – LNAI
On the day this news was published, LNAI declined 2.64%, reflecting a moderate negative market reaction. Argus tracked a peak move of +20.0% during that session. Argus tracked a trough of -13.8% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $285K from the company's valuation, bringing the market cap to $10.52M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Biotechnology group were flagged in the momentum scanner, and with LNAI down 3.21%, the setup points to a stock-specific reaction around listing compliance rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 04 | Financing & acquisition | Positive | +1.5% | Completed $20M Series B preferred issuance to acquire CNS delivery and IP. |
| Apr 15 | Partnership LOI | Positive | -4.7% | Subsidiary signed LOI to build rare disease cohorts for pharma partnerships. |
| Apr 07 | Defense collaboration | Positive | +39.8% | Announced multi-year, revenue-generating defense collaboration using AI platform. |
| Mar 26 | Strategic transaction | Positive | +22.9% | Executed $20M deal for BBB CNS platform via fixed-price convertible preferred. |
| Mar 19 | Consortium launch | Positive | -4.2% | Launched national chemical defense consortium targeting large U.S. programs. |
The stock often reacts positively to strategic and financing announcements, though two recent partnership/consortium updates saw negative next-day moves.
Over the past few months, Lunai Bioworks has combined strategic CNS acquisitions, AI‑driven defense collaborations, and rare‑disease cohort building. Notable deals include two $20M CNS-related transactions and a revenue‑generating defense collaboration that drove a 39.75% move. Today’s reverse split follows this expansion phase and prior Nasdaq bid-price concerns, connecting ongoing listing-compliance efforts with the company’s broader CNS and defense strategy.
Market Pulse Summary
This announcement details a 1-for-8 reverse stock split designed to lift the share price toward Nasdaq’s $1.00 minimum bid requirement, following a prior 1-for-10 split. The move reduces outstanding shares from 36,271,119 to 4,533,890 without changing par value or authorized shares. Investors may watch how the post-split price behaves relative to listing compliance and how it intersects with the company’s ongoing CNS and defense initiatives.
Key Terms
reverse stock split financial
CUSIP regulatory
AI-generated analysis. Not financial advice.
The Company's Common Stock will trade under a new CUSIP number, 29350E302 following the effectiveness of the Reverse Stock Split.
At the Company's Special Meeting of Stockholders held on May 8, 2026, the Company's stockholders approved a proposal authorizing the Company's Board of Directors to amend the Company's Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio in the range of 1-for-3 to 1-for-30, inclusive, with the exact ratio to be determined by the Board in its sole discretion and publicly announced prior to the effective time of the Reverse Stock Split. The Board of Directors subsequently approved the final 1-for-8 Reverse Stock Split ratio.
The Reverse Stock Split is intended primarily to increase the market price per share of the Company's Common Stock to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of at least
As a result of the Reverse Stock Split, every 8 shares of issued and outstanding Common Stock will automatically be combined into one issued and outstanding share of Common Stock. The Reverse Stock Split will not change the par value of the Common Stock or the number of authorized shares of Common Stock. The Reverse Stock Split will reduce the number of issued and outstanding shares of Common Stock from approximately 36,271,119 shares to approximately 4,533,890 shares, subject to adjustment for the treatment of fractional shares.
No fractional shares will be issued in connection with the Reverse Stock Split. Any fractional share that would otherwise result from the Reverse Stock Split will be automatically rounded up to the next whole share at the registered stockholder or DTC participant level, as applicable. Registered stockholders holding shares in book-entry form will receive information from the Company's transfer agent regarding their post-split holdings. Beneficial owners holding shares through a bank, broker or other nominee will have their positions adjusted in accordance with the procedures of their bank, broker or nominee.
The Company's transfer agent, Securities Transfer Corporation, will act as exchange agent for the Reverse Stock Split. Stockholders holding shares electronically in book-entry form are not required to take any action to receive post-split shares.
Proportionate adjustments will be made, as appropriate and in accordance with the terms of the applicable instruments, to the number of shares of Common Stock issuable upon the exercise, vesting, conversion or exchange of our outstanding options, warrants, restricted stock units and other convertible or exercisable securities, as well as to the exercise or conversion prices thereof and to share reserves under our equity compensation plans.
Lunai Bioworks (Nasdaq: LNAI) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform. Lunai combines clinical data, machine learning, and in vivo validation to identify disease biology and develop precision therapeutics. The Company is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the expected timing and effectiveness of the Reverse Stock Split, the expected commencement of split-adjusted trading, the Company's ability to regain or maintain compliance with Nasdaq continued listing requirements, and the expected effects of the Reverse Stock Split on the Company's capitalization, trading price, liquidity and stockholders. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks that the Reverse Stock Split may not result in a sustained increase in the market price of the Common Stock; may result in reduced liquidity, wider bid-ask spreads or increased volatility; may not enable the Company to regain or maintain compliance with Nasdaq Listing Rule 5550(a)(2) or other Nasdaq continued listing requirements; may be subject to Nasdaq, FINRA, DTC or other processing delays; and may be affected by general market conditions, trading prices, investor acceptance and the determinations of the Nasdaq Hearings Panel. Additional risks and uncertainties are described in the Company's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-inc-announces-reverse-stock-split-302777713.html
SOURCE Lunai Bioworks Inc.